The effect of RTX-IgG2 was further validated on Raji B-cell lymphoma cells, which express lower levels of CD20, CD47, and CD59 compared to Granta-519 cells (Figure 7A, Supplementary Figure S6A). This evidence concerns the gene CD59 and B-cell non-Hodgkin lymphoma.